Texas uni loses bid to shield cancer vaccine patents from IPRs

The University of Texas (UT) has failed to persuade the US Court of Appeals for the Federal Circuit to review a ruling that prevented it from using sovereign immunity to protect its cancer vaccine patents from inter partes reviews (IPRs).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Texas Uni’s sovereign immunity fail went as expected

4 March 2021 The result of the sovereign immunity bid mirrored previous cases but we did learn something about the opinions of Justices on the issue, says Gary Frischling of Milbank.

Americas

Texas uni wants Supreme Court to settle state sovereignty rules

12 March 2020 The University of Texas has asked the Supreme Court to rule that state-owned institutions should escape the normal rules determining the appropriate venue for filing patent lawsuits.

Americas

Texas universities sue J&J subsidiary over biodegradable fibres

17 November 2017 A group of 14 educational institutions in Texas and biotech company TissueGen have sued a subsidiary of Johnson & Johnson for infringing two patents covering biodegradable fibres.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Texas uni loses bid to shield cancer vaccine patents from IPRs

More on this story

Editor's picks

Editor's picks

More features